Keros Therapeutics Inc (KROS)

EBITDA Growth

13.03%

Quarterly · Period ending:

KROS logo

KROS EBITDA Growth

Year-over-year change vs the same period a year earlier

Latest reported13.03%
KROS Quarterly EBITDA YoY % (-355.72% → 13.03%)
High-resolution chart · PNG

KROS ebitda growth history

Quarterly. Dates are reporting period ends; fiscal years can differ from calendar years.

Keros Therapeutics Inc EBITDA Growth — Quarterly
Period endingEBITDA Growth
13.0269%
-114.6722%
15.6715%
84.216%
27.5923%
470.7963%
27.1377%
-34.1881%
-20.4668%
-20.2037%
-35.1627%
-67.7715%
-38.4153%
-48.0434%
-511.7635%
-15.5801%
-73.5866%
-52.7993%
54.3679%
-69.1272%
-45.3031%
-31.2943%
-2,780.4348%
-242.6525%
-380.5755%
-355.7159%
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.